| Literature DB >> 24053646 |
Mei-Yang Xi1, Jian-Min Jia, Hao-Peng Sun, Zhong-Ying Sun, Jie-Wei Jiang, Ya-Jing Wang, Min-Ye Zhang, Jun-Feng Zhu, Li-Li Xu, Zheng-Yu Jiang, Xin Xue, Ming Ye, Xi Yang, Yuan Gao, Lei Tao, Xiao-Ke Guo, Xiao-Li Xu, Qing-Long Guo, Xiao-Jin Zhang, Rong Hu, Qi-Dong You.
Abstract
Nrf2-mediated activation of ARE regulates expression of cytoprotective enzymes against oxidative stress, inflammation, and carcinogenesis. We have discovered a novel structure (1) as an ARE inducer via luciferase reporter assay to screen the in-house database of our laboratory. The potency of 1 was evaluated by the expression of NQO-1, HO-1, and nuclear translocation of Nrf2 in HCT116 cells. In vivo potency of 1 was studied using AOM-DSS models, showing that the development of colorectal adenomas was significantly inhibited. Administration with 1 lowered the expression of IL-6, IL-1β, and promoted Nrf2 nuclear translocation. These results indicated that 1 is a potent Nrf2/ARE activator, both in vitro and in vivo. Forty-one derivatives were synthesized for SAR study, and a more potent compound 17 was identified. To our knowledge, this is a potent ARE activator. Besides, its novel structure makes it promising for further optimization.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24053646 DOI: 10.1021/jm400944k
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446